Document is current
Any future updates will be listed below
-
Authors
Fernandez, Elizabeth G.
Mai, Wilson X. https://orcid.org/0000-0002-2977-5673
Song, Kai
Bayley, Nicholas A. https://orcid.org/0000-0003-0489-0592
Kim, Jiyoon
Zhu, Henan
Pioso, Marissa
Young, Pauline
Andrasz, Cassidy L.
Cadet, Dimitri https://orcid.org/0000-0003-3518-608X
Liau, Linda M. https://orcid.org/0000-0002-4053-0052
Li, Gang
Yong, William H.
Rodriguez, Fausto J.
Dixon, Scott J. https://orcid.org/0000-0001-6230-8199
Souers, Andrew J. https://orcid.org/0009-0002-5965-0633
Li, Jingyi Jessica https://orcid.org/0000-0002-9288-5648
Graeber, Thomas G. https://orcid.org/0000-0001-8574-9181
Cloughesy, Timothy F. https://orcid.org/0000-0002-8656-7483
Nathanson, David A. https://orcid.org/0000-0002-4919-9159
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P50CA211015, R01CA227089)
- License Information
-
More Information
Article History
Received: 28 May 2024
Accepted: 3 November 2024
First Online: 21 November 2024
Competing interests
: The authors declare the following competing interests, D.A.N. is a co-founder of Trethera Corporation and has equity in the company. D.A.N. and T.F.C. are co-founders of Katmai Pharmaceuticals and have equity in the company. T.G.G. has consulting and equity agreements with Auron Therapeutics, Boundless Bio, Coherus BioSciences and Trethera Corporation. E.G.F., W.X.M., K.S., N.A.B., J.K., H.Z., M.P., P.Y., C.L.A., D.C., L.M.L., G.L., W.H.Y., F.J.R., S.J.D., A.J.S., and J.J.L. have no competing interests to declare.
